Transplant News and Research

RSS

Taligen Therapeutics announces closing on $10M tranche of Series B financing

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has closed on a $10 million tranche of a Series B financing, based on substantial progress with the company's product pipeline including advancing the lead product candidate, TT30, toward clinical development.

23 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

Noninvasive monitoring of cardiac allograft vasculopathy with fast MR imaging

Cardiac allograft vasculopathy (CAV), also known as chronicle rejection, is a leading cause of graft (foreign heart) loss and death in patients who survive the first year after heart transplantation. The typical pathological change of CAV is gradually thickening of coronary wall in "foreign" heart due to continuous immunological reaction between donated heart and the host. In some cases, undetected CAV may silently cause graft failure with global myocardial ischemia without any documented infarction signs. Thus, continually monitoring development of asymptomatic CAV is important for selecting prophylactic strategies to get better prognosis. However, most current examinations of detecting CAV are invasive and with certain risks.

22 Aug 2010

NBA player Alonzo Mourning uses celebrity fame to fight kidney disease

In October 2000, Mourning was diagnosed with focal segmental glomerular sclerosis (FSGS), a kidney disease that causes scarring in the glomeruli, the blood vessels in the kidneys that filter the blood to make urine.

21 Aug 2010

Study finds Hispanics, Asians less likely to receive liver transplants

Researchers at the University of Michigan and Arbor Research Collaborative for Health, both in Ann Arbor, have identified geographic variation as a key factor accounting for disparities in access to liver transplantation among racial and ethnic groups.

20 Aug 2010

Cedars-Sinai opens Advanced Heart Failure Unit in California

The Cedars-Sinai Heart Institute has opened an innovative 30-bed in-patient unit dedicated to providing advanced heart failure patients with an intensive, multidisciplinary approach to inpatient care.

20 Aug 2010

St. Vincent's Hospital performs Australia's first implant of SynCardia temporary Total Artificial Heart

On Aug. 5, St. Vincent's Hospital in Sydney performed Australia's first implant of the SynCardia temporary Total Artificial Heart. The patient, a 50-year-old male suffering from total heart failure, is the first recipient of the Total Artificial Heart in the Southern Hemisphere. The surgery was performed by heart surgeons Drs. Phillip Spratt and Paul Jansz.

20 Aug 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Donor kidneys from deceased as good as those from brain-dead: Study

According to a new study from the UK, transplanted kidneys from patients whose hearts have stopped perform just as well as those from patients who are brain-dead but still alive. The former have been earlier considered to be weaker since the heart had stopped pumping blood into them before transplant. The study was published online by the The Lancet.

20 Aug 2010

Two-day LEAN training course for healthcare professionals

The two-day course is a didactic and hands-on introduction to LEAN management philosophy and manufacturing-based work rules and tools designed to prepare physicians, administrators, and technical support staff for the realities and potential successes of practicing in a LEAN environment. The sessions are not only oriented to laboratory medicine but also adapted to the processes encountered in clinical services as well.

19 Aug 2010

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

19 Aug 2010

Study finds factor behind alcohol use disorder after liver transplantation

Patients who receive a liver transplant due to alcoholic liver disease need to demonstrate periods of abstinence and often attend addiction treatment before transplantation. However, alcohol use disorders can recur, as can other diseases requiring transplantation, and thus alcohol use after liver transplantation is not uncommon.

19 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Before today, millions of Canadians living with chronic kidney disease did not have a strong online advocacy presence. Improving Patient Advocacy in Chronic Kidney Disease and The Kidney Foundation of Canada are now joining forces to provide an effective resource. Together, they are launching www.impackd.ca, a microsite of www.kidney.ca that is specifically designed for Canadians affected by chronic kidney disease.

17 Aug 2010

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Looking to gain further understanding about the impact of cancer on patients and families, The Cancer Institute of New Jersey (CINJ) is expanding its Quality and Outcomes in Cancer Care (QOCC) Research Program by welcoming nationally-recognized population science researcher Sharon Manne, PhD. Dr. Manne, who is the recipient of major grant awards from the National Institutes of Health (NIH) for her work in behavioral science, was most recently at the Fox Chase Cancer Center in Philadelphia. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

17 Aug 2010

Hepatitis C rather than Donor Risk Index is major contributor to poor graft survival in transplant patients

The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.

17 Aug 2010

BrickHouse Security, National Kidney Registry implement real-time GPS tracking system for organ shipment

BrickHouse Security, a leading provider of security and surveillance products to businesses and consumers, today announced that, in partnership with the National Kidney Registry (NKR), they have implemented the first real-time GPS tracking system for the shipment of living donor organs.

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Transplant News and Research

Taligen Therapeutics announces closing on $10M tranche of Series B financing

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Noninvasive monitoring of cardiac allograft vasculopathy with fast MR imaging

NBA player Alonzo Mourning uses celebrity fame to fight kidney disease

Study finds Hispanics, Asians less likely to receive liver transplants

Cedars-Sinai opens Advanced Heart Failure Unit in California

St. Vincent's Hospital performs Australia's first implant of SynCardia temporary Total Artificial Heart

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Donor kidneys from deceased as good as those from brain-dead: Study

Two-day LEAN training course for healthcare professionals

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Study finds factor behind alcohol use disorder after liver transplantation

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

FDA grants orphan drug designation to NephRx's lead product NX001

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Hepatitis C rather than Donor Risk Index is major contributor to poor graft survival in transplant patients

BrickHouse Security, National Kidney Registry implement real-time GPS tracking system for organ shipment

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News